These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 30862694)

  • 1. PAK Kinase Inhibition Has Therapeutic Activity in Novel Preclinical Models of Adult T-Cell Leukemia/Lymphoma.
    Chung EY; Mai Y; Shah UA; Wei Y; Ishida E; Kataoka K; Ren X; Pradhan K; Bartholdy B; Wei X; Zou Y; Zhang J; Ogawa S; Steidl U; Zang X; Verma A; Janakiram M; Ye BH
    Clin Cancer Res; 2019 Jun; 25(12):3589-3601. PubMed ID: 30862694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of anti-human CADM1 monoclonal antibodies as a potential therapy for adult T-cell leukemia/lymphoma.
    Chilmi S; Nakahata S; Fauzi YR; Ichikawa T; Tani C; Suwanruengsri M; Yamaguchi R; Matsuura T; Kurosawa G; Morishita K
    Int J Hematol; 2020 Oct; 112(4):496-503. PubMed ID: 32656636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined inhibition of receptor tyrosine and p21-activated kinases as a therapeutic strategy in childhood ALL.
    Siekmann IK; Dierck K; Prall S; Klokow M; Strauss J; Buhs S; Wrzeszcz A; Bockmayr M; Beck F; Trochimiuk M; Gottschling K; Martens V; Khosh-Naucke M; Gerull H; Müller J; Behrmann L; Blohm M; Zahedi RP; Jeremias I; Sickmann A; Nollau P; Horstmann MA
    Blood Adv; 2018 Oct; 2(19):2554-2567. PubMed ID: 30301811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PAK1 overexpression promotes cell proliferation in cutaneous T cell lymphoma via suppression of PUMA and p21.
    Wang Y; Gu X; Li W; Zhang Q; Zhang C
    J Dermatol Sci; 2018 Apr; 90(1):60-67. PubMed ID: 29307600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PAK1, PAK1Δ15, and PAK2: similarities, differences and mutual interactions.
    Grebeňová D; Holoubek A; Röselová P; Obr A; Brodská B; Kuželová K
    Sci Rep; 2019 Nov; 9(1):17171. PubMed ID: 31748572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-adult T‑cell leukemia/lymphoma activity of cerdulatinib, a dual SYK/JAK kinase inhibitor.
    Ishikawa C; Senba M; Mori N
    Int J Oncol; 2018 Oct; 53(4):1681-1690. PubMed ID: 30066853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversal of CYLD phosphorylation as a novel therapeutic approach for adult T-cell leukemia/lymphoma (ATLL).
    Xu X; Kalac M; Markson M; Chan M; Brody JD; Bhagat G; Ang RL; Legarda D; Justus SJ; Liu F; Li Q; Xiong H; Ting AT
    Cell Death Dis; 2020 Feb; 11(2):94. PubMed ID: 32024820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pak1 kinase links ErbB2 to β-catenin in transformation of breast epithelial cells.
    Arias-Romero LE; Villamar-Cruz O; Huang M; Hoeflich KP; Chernoff J
    Cancer Res; 2013 Jun; 73(12):3671-82. PubMed ID: 23576562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expansion of BCR/ABL1
    Edlinger L; Berger-Becvar A; Menzl I; Hoermann G; Greiner G; Grundschober E; Bago-Horvath Z; Al-Zoughbi W; Hoefler G; Brostjan C; Gille L; Moriggl R; Spittler A; Sexl V; Hoelbl-Kovacic A
    Br J Haematol; 2017 Oct; 179(2):229-241. PubMed ID: 28707321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor effects of chloroquine/hydroxychloroquine mediated by inhibition of the NF-κB signaling pathway through abrogation of autophagic p47 degradation in adult T-cell leukemia/lymphoma cells.
    Fauzi YR; Nakahata S; Chilmi S; Ichikawa T; Nueangphuet P; Yamaguchi R; Nakamura T; Shimoda K; Morishita K
    PLoS One; 2021; 16(8):e0256320. PubMed ID: 34407152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting P21-activated kinase suppresses proliferation and enhances chemosensitivity in T-cell lymphoblastic lymphoma.
    Su N; Fang Y; Chen X; Chen X; Xia Z; Huang H; Xia Y; Liu P; Tian X; Cai Q
    Blood Sci; 2023 Oct; 5(4):249-257. PubMed ID: 37941919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cell adhesion molecule-1 (CADM1) expressed on adult T-cell leukemia/lymphoma cells is not involved in the interaction with macrophages.
    Komohara Y; Ma C; Yano H; Pan C; Horlad H; Saito Y; Ohnishi K; Fujiwara Y; Okuno Y; Nosaka K; Shimosaki S; Morishita K; Matsuoka M; Wakayama T; Takeya M
    J Clin Exp Hematop; 2017 Jul; 57(1):15-20. PubMed ID: 28420814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PAK1 inhibition reduces tumor size and extends the lifespan of mice in a genetically engineered mouse model of Neurofibromatosis Type 2 (NF2).
    Hawley E; Gehlhausen J; Karchugina S; Chow HY; Araiza-Olivera D; Radu M; Smith A; Burks C; Jiang L; Li X; Bessler W; Masters A; Edwards D; Burgin C; Jones D; Yates C; Clapp DW; Chernoff J; Park SJ
    Hum Mol Genet; 2021 Aug; 30(17):1607-1617. PubMed ID: 34075397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protein kinase D1 (PKD1) phosphorylation on Ser
    Chang JK; Ni Y; Han L; Sinnett-Smith J; Jacamo R; Rey O; Young SH; Rozengurt E
    J Biol Chem; 2017 Jun; 292(23):9523-9539. PubMed ID: 28408623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Group I p21-activated kinases in leukemia cell adhesion to fibronectin.
    Kuželová K; Obr A; Röselová P; Grebeňová D; Otevřelová P; Brodská B; Holoubek A
    Cell Adh Migr; 2021 Dec; 15(1):18-36. PubMed ID: 33464167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting PAK4 Inhibits Ras-Mediated Signaling and Multiple Oncogenic Pathways in High-Risk Rhabdomyosarcoma.
    Dasgupta A; Sierra L; Tsang SV; Kurenbekova L; Patel T; Rajapakse K; Shuck RL; Rainusso N; Landesman Y; Unger T; Coarfa C; Yustein JT
    Cancer Res; 2021 Jan; 81(1):199-212. PubMed ID: 33168646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cell death induced by dorsomorphin in adult T-cell leukemia/lymphoma is AMPK-independent.
    Aikawa A; Kozako T; Uchida Y; Yoshimitsu M; Ishitsuka K; Ohsugi T; Honda SI
    FEBS J; 2020 Sep; 287(18):4005-4015. PubMed ID: 32027454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemically Diverse Group I p21-Activated Kinase (PAK) Inhibitors Impart Acute Cardiovascular Toxicity with a Narrow Therapeutic Window.
    Rudolph J; Murray LJ; Ndubaku CO; O'Brien T; Blackwood E; Wang W; Aliagas I; Gazzard L; Crawford JJ; Drobnick J; Lee W; Zhao X; Hoeflich KP; Favor DA; Dong P; Zhang H; Heise CE; Oh A; Ong CC; La H; Chakravarty P; Chan C; Jakubiak D; Epler J; Ramaswamy S; Vega R; Cain G; Diaz D; Zhong Y
    J Med Chem; 2016 Jun; 59(11):5520-41. PubMed ID: 27167326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Small molecule inhibition of group I p21-activated kinases in breast cancer induces apoptosis and potentiates the activity of microtubule stabilizing agents.
    Ong CC; Gierke S; Pitt C; Sagolla M; Cheng CK; Zhou W; Jubb AM; Strickland L; Schmidt M; Duron SG; Campbell DA; Zheng W; Dehdashti S; Shen M; Yang N; Behnke ML; Huang W; McKew JC; Chernoff J; Forrest WF; Haverty PM; Chin SF; Rakha EA; Green AR; Ellis IO; Caldas C; O'Brien T; Friedman LS; Koeppen H; Rudolph J; Hoeflich KP
    Breast Cancer Res; 2015 Apr; 17(1):59. PubMed ID: 25902869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 2-amino-N-{4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-phenyl} acetamide (OSU-03012), a celecoxib derivative, directly targets p21-activated kinase.
    Porchia LM; Guerra M; Wang YC; Zhang Y; Espinosa AV; Shinohara M; Kulp SK; Kirschner LS; Saji M; Chen CS; Ringel MD
    Mol Pharmacol; 2007 Nov; 72(5):1124-31. PubMed ID: 17673571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.